Author

D. Farnell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

D. G. Huntsman· 2 shared A. Cheng· 1 shared A. N. Karnezis· 1 shared B. E. Weissman· 1 shared B. Tessier-Cloutier· 1 shared C. B. Gilks· 1 shared C. Chow· 1 shared D. R. Cochrane· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. G. Huntsman

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Modeling High-grade serous ovarian carcinoma using a combination of in vivo electroporation and CRISPR/Cas9 mediated genome editing

K. Teng, M. J. Ford, K. Harwalkar, Y. Li, D. Farnell, N. Yamanaka, T. N. Tuyet Nhung, D. G. Huntsman, J. Arseneau, Y. Yamanaka

This paper develops a method to generate HGSC mouse models using in vivo electroporation and CRISPR/Cas9, showing that specific gene mutations lead to different tumor characteristics.

bioRxiv · Mar 29, 2021Cancer Biology

Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type

J. X. Ji, D. R. Cochrane, B. Tessier-Cloutier, S. Chen, G. Ho, K. V. Pathak, I. Alcazar, D. Farnell, S. Leung, A. Cheng, C. Chow, S. Colborne, G. Luca Negri, F. Kommoss, A. N. Karnezis, , D. G. Huntsman

This paper identifies ASS1 deficiency in rare ovarian cancers and shows that ADI-PEG20 inhibits tumor growth in ASS1-deficient models.

bioRxiv · Nov 17, 2019 · PreprintCancer Biology